Previous Close | 0.8781 |
Open | 0.8713 |
Bid | 0.9100 x 900 |
Ask | 0.9724 x 900 |
Day's Range | 0.8006 - 0.9297 |
52 Week Range | 0.5000 - 5.5350 |
Volume | |
Avg. Volume | 878,886 |
Market Cap | 49.595M |
Beta (5Y Monthly) | 0.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.1900 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.07 |
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology,
As you might know, Cara Therapeutics, Inc. ( NASDAQ:CARA ) last week released its latest full-year, and things did not...
Cara Therapeutics ( NASDAQ:CARA ) Full Year 2023 Results Key Financial Results Revenue: US$21.0m (down 50% from FY...